FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kei Fukami

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Anatomy

Procedures

Co-author Network

Publications

TOP 3
Rie Manabe; Yosuke Nakayama; Takeki Adachi; Ryotaro Ando; Kei Fukami; Takuma Hazama; Yusuke Kaida; Keisuke Kohno; Takuo Kusumoto; Kazuko Sakai; Seiji Ueda; Yoshifumi Wada; Sho-ichi Yamagishi; Seiya Okuda
Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.
Ayako Ojima; Masayoshi Takeuchi; Kei Fukami; Yuji Ishibashi; Sayaka Maeda; Takanori Matsui; Yuri Nishino; Sho-ichi Yamagishi
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Yuji Ishibashi; Takanori Matsui; Kei-ichiro Nakamura; Keisuke Ohta; Seiya Okuda; Masayoshi Takeuchi; Ryuichiro Tanoue; Katsuhiko Asanuma; Kei Fukami; Sho-ichi Yamagishi
PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kei Fukami (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Rie Manabe; Yosuke Nakayama; Takeki Adachi; Ryotaro Ando; Kei Fukami; Takuma Hazama; Yusuke Kaida; Keisuke Kohno; Takuo Kusumoto; Kazuko Sakai; Seiji Ueda; Yoshifumi Wada; Sho-ichi Yamagishi; Seiya Okuda
Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2013;17 Suppl 1():35-40.
2013: Ayako Ojima; Masayoshi Takeuchi; Kei Fukami; Yuji Ishibashi; Sayaka Maeda; Takanori Matsui; Yuri Nishino; Sho-ichi Yamagishi
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
The American journal of pathology 2013;182(1):132-41.
2013: Yuji Ishibashi; Takanori Matsui; Kei-ichiro Nakamura; Keisuke Ohta; Seiya Okuda; Masayoshi Takeuchi; Ryuichiro Tanoue; Katsuhiko Asanuma; Kei Fukami; Sho-ichi Yamagishi
PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation.
Microvascular research 2013;85():54-8.
2013: Yoshimi Takamiya; Seiji Ueda; Sho-ichi Yamagishi; Ryotaro Ando; Mark E Cooper; Kei Fukami; Ryuji Iwatani; Yusuke Kaida; Kiyomi Koike; Takanori Matsui; Yosuke Nakayama; Yuri Nishino; Nana Obara; Seiya Okuda
Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2013;28(1):55-62.
2012: Takeki Adachi; Ryotaro Ando; Kei Fukami; Yusuke Kaida; Aki Otsuka; Kazuko Sakai; Kenzo Sugi; Seiji Ueda; Sho-ichi Yamagishi; Hisashi Adachi; Seiya Okuda
Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients.
Nephrology (Carlton, Vic.) 2012;17(8):689-94.
2012: Yusuke Kaida; Yosuke Nakayama; Ryotaro Ando; Kei Fukami; Ryuji Iwatani; Seiji Ueda; Sho-ichi Yamagishi; Seiya Okuda
Proteinuria elevates asymmetric dimethylarginine levels via protein arginine methyltransferase-1 overexpression in a rat model of nephrotic syndrome.
Life sciences 2012;91(9-10):301-5.
2012: Sho-ichi Yamagishi; Seiji Ueda; Kei Fukami; Sayaka Maeda; Takanori Matsui; Seiya Okuda
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
Biochimica et biophysica acta 2012;1820(5):663-71.
2012: Kiyomi Koike; Rimi Obata; Atsuko Ohara; Kazuhito Takeda; Maki Toyonaga; Seiji Ueda; Kaoru Ueda; Sho-ichi Yamagishi; Koji Yonemoto; Kei Fukami; Ryuji Iwatani; Seiya Okuda
A new vasculitis activity score for predicting death in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis patients.
American journal of nephrology 2012;35(1):1-6.
2011: Sayaka Maeda; Takanori Matsui; Masayoshi Takeuchi; Yumiko Yoshida; Ryoji Yamakawa; Kei Fukami; Sho-ichi Yamagishi
Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
Pharmacological research : the official journal of the Italian Pharmacological Society 2011;63(3):241-8.
2011: Makio Nagano; Kei Fukami; Sho-ichi Yamagishi; Kazuko Sakai; Yusuke Kaida; Takafumi Matsumoto; Takuma Hazama; Masahiro Tanaka; Seiji Ueda; Seiya Okuda
Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients.
Nephrology (Carlton, Vic.) 2011;16(3):299-303.
2011: Kiyomi Koike; Satoshi Morishige; Kei Fukami; Kensei Taguchi; Kazuaki Yakushiji; Takashi Okamura; Seiya Okuda
[Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2011;100(1):179-81.
2011: Ayako Fujimi-Hayashida; Seiji Ueda; Sho-ichi Yamagishi; Yusuke Kaida; Ryotaro Ando; Yosuke Nakayama; Kei Fukami; Seiya Okuda
Association of asymmetric dimethylarginine with severity of kidney injury and decline in kidney function in IgA nephropathy.
American journal of nephrology 2011;33(1):1-6.
2010: Junko Yoshimura; Kei Fukami; Kiyomi Koike; Makio Nagano; Takafumi Matsumoto; Ryuji Iwatani; Takuo Kusumoto; Takuma Hazama; Seiji Ueda; Hisashi Adachi; Yuji Hirai; Konomi Takasu; Koichi Ohshima; Sho-ichi Yamagishi; Seiya Okuda
Interstitial Foxp3-positive T cells may predict renal survival in patients with myeroperoxidase anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.
Clinical and experimental pharmacology & physiology 2010;37(9):879-83.
2010: Takanori Matsui; Sho-ichi Yamagishi; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda
Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
Biochemical and biophysical research communications 2010;398(2):326-30.
2010: Takanori Matsui; Sho-ichi Yamagishi; Seiji Ueda; Kei Fukami; Seiya Okuda
Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis and injury in vitro.
Protein and peptide letters 2010;17(1):74-7.
2010: Takanori Matsui; Sho-ichi Yamagishi; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda
Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.
Pharmacological research : the official journal of the Italian Pharmacological Society 2010;61(1):34-9.
2009: Takanori Matsui; Sho-ichi Yamagishi; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
Biochemical and biophysical research communications 2009;385(2):269-72.
2009: Seiji Ueda; Sho-ichi Yamagishi; Yuriko Matsumoto; Yusuke Kaida; Ayako Fujimi-Hayashida; Kiyomi Koike; Hideharu Tanaka; Kei Fukami; Seiya Okuda
Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD).
Life sciences 2009;84(23-24):853-6.
2009: Toshiko Fujimura; Sho-ichi Yamagishi; Seiji Ueda; Kei Fukami; Ryo Shibata; Yuriko Matsumoto; Yusuke Kaida; Ayako Hayashida; Kiyomi Koike; Takanori Matsui; Kei-ichiro Nakamura; Seiya Okuda
Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009;24(5):1397-406.
2009: Ryo Shibata; Seiji Ueda; Sho-ichi Yamagishi; Yusuke Kaida; Yuriko Matsumoto; Kei Fukami; Ayako Hayashida; Hidehiro Matsuoka; Seiya Kato; Masumi Kimoto; Seiya Okuda
Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009;24(4):1162-9.
2009: Sho-ichi Yamagishi; Takanori Matsui; Seiji Ueda; Kei Fukami; Seiya Okuda
Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.
Current drug metabolism 2009;10(2):159-63.
2009: Makio Nagano; Kei Fukami; Sho-ichi Yamagishi; Seiji Ueda; Yusuke Kaida; Takafumi Matsumoto; Junko Yoshimura; Takuma Hazama; Yoshimi Takamiya; Takuo Kusumoto; Shojiro Gohara; Hideharu Tanaka; Hisashi Adachi; Seiya Okuda
Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease.
American journal of nephrology 2009;29(2):109-15.
2008: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Seiji Ueda; Kei Fukami; Seiya Okuda
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Expert opinion on investigational drugs 2008;17(7):983-96.
2008: Kei Fukami; Sho-ichi Yamagishi; Seiji Ueda; Seiya Okuda
Role of AGEs in diabetic nephropathy.
Current pharmaceutical design 2008;14(10):946-52.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Hiroyoshi Inoue; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda; Tsutomu Imaizumi
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
Microvascular research 2008;75(1):130-4.
2007: Sho-ichi Yamagishi; Kei Fukami; Seiji Ueda; Seiya Okuda
Molecular mechanisms of diabetic nephropathy and its therapeutic intervention.
Current drug targets 2007;8(8):952-9.
2007: Seiji Ueda; Sho-ichi Yamagishi; Yuriko Matsumoto; Kei Fukami; Seiya Okuda
Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
Clinical and experimental nephrology 2007;11(2):115-21.
2007: Kei Fukami; Sho-ichi Yamagishi; Seiji Ueda; Seiya Okuda
Novel therapeutic targets for diabetic nephropathy.
Endocrine, metabolic & immune disorders drug targets 2007;7(2):83-92.
2007: Yuriko Matsumoto; Seiji Ueda; Sho-ichi Yamagishi; Kyoko Matsuguma; Ryo Shibata; Kei Fukami; Hidehiro Matsuoka; Tsutomu Imaizumi; Seiya Okuda
Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
Journal of the American Society of Nephrology : JASN 2007;18(5):1525-33.
2005: Ryo Sugano; Hidehiro Matsuoka; Nobuya Haramaki; Hidekazu Umei; Eiko Murase; Kei Fukami; Shuji Iida; Hisao Ikeda; Tsutomu Imaizumi
Polymorphonuclear leukocytes may impair endothelial function: results of crossover randomized study of lipid-lowering therapies.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(6):1262-7.
2005: Hidemi Nishida; Masatoshi Ishibashi; Yuji Hiromatsu; Hayato Kaida; Kenkichi Baba; Ikuyo Miyake; Hirofumi Ikedo; Seiya Kato; Kei Fukami; Shuji Iida; Seiya Okuda
Comparison of histological findings and parathyroid scintigraphy in hemodialysis patients with secondary hyperparathyroid glands.
Endocrine journal 2005;52(2):223-8.
2004: Kei Fukami; Seiji Ueda; Sho-ichi Yamagishi; Seiya Kato; Yosuke Inagaki; Masayoshi Takeuchi; Yoshihiro Motomiya; Richard Bucala; Shuji Iida; Kiyoshi Tamaki; Tsutomu Imaizumi; Mark E Cooper; Seiya Okuda
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction.
Kidney international 2004;66(6):2137-47.